Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. The principal activities of the Company are the development, manufacture and marketing of a range of generic, branded and in-licensed pharmaceutical products. The firm operates through three segments: Injectables, Branded and Generics. The Injectables segment supplies hospitals across its markets with generic injectable products, supported by its manufacturing facilities in the United States, Europe and Middle East/North Africa (MENA). The company is also engaged in the finished dosage form (FDF) business and has a manufacturing facility in Cleveland, Ohio. The Branded segment supplies branded generics and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. The Generics segment supplies oral and other non-injectable generic and specialty products to the United States retail market, leveraging its manufacturing facility in Columbus, Ohio.
How did HKMPF's recent EPS compare to expectations?
The most recent EPS for Hikma Pharmaceuticals PLC is $, expectations of $.
How did Hikma Pharmaceuticals PLC HKMPF's revenue perform in the last quarter?
Hikma Pharmaceuticals PLC revenue for the last quarter is $
What is the revenue estimate for Hikma Pharmaceuticals PLC?
According to of Wall street analyst, the revenue estimate of Hikma Pharmaceuticals PLC range from $ to $
What's the earning quality score for Hikma Pharmaceuticals PLC?
Hikma Pharmaceuticals PLC has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Hikma Pharmaceuticals PLC report earnings?
Hikma Pharmaceuticals PLC next earnings report is expected in 2026-05-27
What are Hikma Pharmaceuticals PLC's expected earnings?
Hikma Pharmaceuticals PLC expected earnings is $, according to wall-street analysts.
Did Hikma Pharmaceuticals PLC beat earnings expectations?
Hikma Pharmaceuticals PLC recent earnings of $ expectations.